When dealing with market risk under the Basel II Accord, variation pays in the form of lower capital requirements and higher profits. Typically, GARCH type models are chosen to forecast Value-at-Risk (VaR) using a single risk model. In this paper we illustrate two useful variations to the standard mechanism for choosing forecasts, namely: (i) combining different forecast models for each period,...

Reconciliation is the process of providing a consistent view of the data imported from different sources. Despite some efforts reported in the literature for providing data reconciliation solutions with asynchronous collaboration, the challenge of reconciling data when multiple users work asynchronously over local copies of the same imported data has received less attention. In this paper, we p...

Explaination about the exist of music motif part a.k.a materials unity, made by a composing technique its build form, outcome from composer’s decision to compose or make composition with concepting reference accord values and composer takes learn understand process are elements that explaining in this article. Things take eventually give way developing. The does based on method how performing a...

In Australia, as in most countries, capital adequacy regulation of banks and other regulated deposit-taking institutions is based on guidelines contained in the Committee’s Capital Accord. APRA therefore takes a close interest in the evolution of the Accord and is keen to contribute to its on-going development. In light of rapid advances in methods for measuring and managing risk in recent year...

The Action to Control Cardiovascular Disease in Diabetes (ACCORD) blood pressure trial is an unmasked, open-label, randomized trial with a sample size of 4,733 participants. This report describes the rationale, design, and methods of the blood pressure interventions in ACCORD. Participants eligible for the blood pressure trial are randomized to 1 of 2 groups with different treatment goals: syst...

E arly cessation of the intensive glycemic treatment arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial because of a 22% excess of all-cause mortality compared with the standard arm (1) came as an unpleasant surprise to many observers. Since then, considerable discussion of the significance of this result has ensued along with various theories as to why it occurred. In ...